NOSSAMAN LLP for AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Repeal of LIFO (Last in, First Out).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Medicare/Medicaid MMM
(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction). Sustainable Growth Rate.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Pharmacy PHA
H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| PAUL S QUINN | — |
| SHERRY HARPER WIDICUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.